CORRUPTION IN MEDICAL PRACTICE: WHERE DO WE STAND?
AbstractCorruption in health care sector affects all countries, including theUnited States,ChinaandIndia. Pakistanis no exception. It is preventing people from having access to the quality medical care. Corruption in medical practice include ordering unnecessary investigations, and procedures for kickbacks and commissions; significant absenteeism, which adversely affects patient care; and the conflict of interest within the physician-pharmaceutical nexus, which exploits patients. To overcome corruption there is need to establish a framework for accountability, eliminating the physician-pharmaceutical nexus; and emphasizing medical ethics at the undergraduate and postgraduate levels. It is also important to open a dialogue amongst health care professionals and encourage the establishment of an ethical health care system in Pakistan.
Ofosu-Amaah WP, Soopramanien R, Uprety K. Combating Corruption : A Comparative Review of Selected Legal Aspects of State Practice and Major International Initiatives. J Financial Crime 2007;14(3)250–63.
Kohler JC. Fighting Corruption in the Health Sector: Methods, Tools and Good Practices. New York: United Nations Development Programme; 2011.
Global Corruption Report 2006. London: Transparency International 2005;1–378.
Vian T. Review of corruption in the health sector: theory, methods and interventions. Health Policy Plan 2008;23(2):83–94.
Transparency International UK. Pharmaceuticals and healthcare programme. [Internet] [Cited 2015 Aug 15] Available at: www.transparency.org.uk/our-work/pharmaceutical-a-healthcare-programme
Kessel M. Restoring the pharmaceutical industry’s reputation. Nat Biotechnol. 2014;32(10):983–90.
Rose-Ackerman S, Tan Y. Corruption in the Procurement of Pharmaceuticals and Medical Equipment in China: The Incentives Facing Multinationals, Domestic Firms and Hospital Officials. Yale Law Econ Res Pap. 2014;498.
Bhawan L, Nagar L. India Corruption Study 2005 [Internet]. New Delhi: Transparency International India; [cited 2015 Aug 15] p. 228. Available from: http://www.transparencyindia.org/resource/survey_study/India%20Corruption%20Study%202005.pdf
Transparency International. Corruption perceptions index 2011. Transparency International; 2011.
Transparency International. Corruption in Public Services; Perceived Corruption in Health Sector. Berlin, Germany: Transparency International; 2002.
Husain S. Medical Profession in Pakistan has been infected with Commercialization and Corruption Virus. Pulse Int 2012. Available from: http://www.pulsepakistan.com/index.php/main-news-nov-15-12/124-medical-profession-in-pakistan
Ul-Haque A. Physicians’ Arrest on Receiving Commission on Referring Laboratory Tests. Int J Pathol 2011;9(2):49–50.
Naveed M. Health System of Pakistan & the Increasing Medical Malpractices [Internet]. [cited 2015 Aug 15]. Available from: http://www.pakistanherald.com/Articles/Health-System-of-Pakistan-and-the-Increasing-Medical-Malpractices-3071
Agboatwalla M, Niazi T. ‘Extent of Absenteeism in the Health Sector in Pakistan’. TAP Workshop, Washington DC 23rd –26th March 2010.
Nishtar S. Corruption and Health: Does Corruption Lurk in the Health Sector of Pakistan? The News International. August 5, 2007. [Internet] [Cited 2015 Aug 15] Available from: http://www.heartfile.org/pdf/22_Corruption.pdf
Nishtar S. The Gateway Paper; Health System in Pakistan – a Way Forward. Islamabad, Pakistan: Pakistan’s Health Policy Forum and Heartfile; 2006. [Internet] [Cited 2015 Aug 15] available from: http://heartfile.org/pdf/phpf-GWP.pdf
Gadit AAM. Corruption in medical practice: how far have we gone? J Pak Med Assoc 2011;61(1):93–4.
Patients suffer due to nexus of doctors, drug companies. daily time. [Internet]. [published 2014-Apr-10, Cited 2015 Aug 8]. Available from: http://www.dailytimes.com.pk/sindh/10-Apr-2014/patients-suffer-due-to-nexus-of-doctors-drug-companies
Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med 2003;163(18):2213–8.
Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med 1993;22(10):1593–6.
Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 1995;153(5):553–9.
Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. CMAJ 1996;155(9):1243–8.
McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1990;264(13):1693–7.
Banks JW, Mainous AG. Attitudes of Medical School Faculty toward Gifts from the Pharmaceutical Industry. Acad Med 1992;67(9):610–2.
Keim SM, Sanders AB, Witzke DB, Dyne P, Fulginiti JW. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Ann Emerg Med 1993;22(10):1576–81.
Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290(2):252–5.
Khan MM. Why I declined an invitation to a drug company seminar. BMJ 2007;335(7625):887.
Nishtar S, Bhutta ZA, Jafar TH, Ghaffar A, Akhtar T, Bengali K, et al. Health reform in Pakistan: a call to action. Lancet 2013;381(9885):2291–7.
WHO. Good Governance for Medicines Programme. World Health Organization; 2009. [Internet] [Cited 2015 Aug 12] http://apps.who.int/medicinedocs/documents/s16218e/s16218e.pdf